Debbie Wang

Associate

  • JD, University of Toronto Faculty of Law, 2017; Senior Editor, University of Toronto Faculty of Law Review
  • BA (Psychology, Interdisciplinary Life Sciences), McGill University, 2014

Qualifications

  • New York, 2018
  • LMG Life Sciences Americas Awards “Impact Deal of the Year” for advising Pfizer in $11.6 billion acquisition of Biohaven Pharmaceuticals (2022)

Debbie Wang

Associate

Debbie Wang is an associate in the mergers and acquisitions group. Debbie has experience representing public and private companies, financial institutions and investors in a broad range of transactional matters, including mergers and acquisitions, financings and other strategic transactions, as well as advising on general corporate and commercial matters.

Prior to joining Ropes & Gray, Debbie was an associate at a leading Canadian law firm and an international law firm in New York. 

Experience

  • Represented Pfizer Inc. in its:
    • $11.6 billion acquisition of Biohaven Pharmaceuticals
    • $6.7 billion acquisition of Arena Pharmaceuticals, Inc. 
  • Represented Medtronic plc in its $1.1 billion acquisition of Intersect ENT, Inc.  
  • Represented Detour Gold Corporation in the C$4.9B acquisition of all of its issued and outstanding common shares by Kirkland Lake Gold Ltd.*
  • Represented Discount Car and Truck Rentals Ltd. in its sale to Enterprise Rent-A-Car Canada Company.*
  • Represented Alacer Gold Corp. in its $5B at-market merger of equals with SSR Mining Inc.*
  • Represented various public company and financial institution clients with capital markets transactions.*
  • Represented private equity and pension funds on M&A and other strategic transactions.*
  • Advised public company clients on continuous disclosure and corporate governance matters.*

*Experience prior to Ropes & Gray

  • JD, University of Toronto Faculty of Law, 2017; Senior Editor, University of Toronto Faculty of Law Review
  • BA (Psychology, Interdisciplinary Life Sciences), McGill University, 2014

Qualifications

  • New York, 2018
  • LMG Life Sciences Americas Awards “Impact Deal of the Year” for advising Pfizer in $11.6 billion acquisition of Biohaven Pharmaceuticals (2022)
Cookie Settings